These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Other 2004-002050-66 INTERRUPCIÓN DEL TRATAMIENTO EN NIÑOS CON INFECCIÓN CRÓNICA POR VIH not-yet-due
Ongoing 2005-004433-18 Plasma pharmacokinetic study of once versus twice daily abacavir as part of combination antiretroviral therapy in children with HIV-1 infection aged 3 months to <36 months not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-012947-40 BREATHER (PENTA 16): Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIV 2016-09-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-013648-35 A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-dailyversus once-daily Iopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral the... 2014-06-06 bad-data
Not reported 2011-001515-31 EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL 2014-12-17 due-trials
Not reported 2011-001521-25 : NEOMERO 2: FARMACOCINÉTICA Y SEGURIDAD DE MEROPENEM EN NIÑOS DE EDADES HASTA 90 DÍAS (INCLUSIVE) CON MENINGITIS PROBABLE O CONFIRMADA: ENSAYO MULTICÉNTRICO EUROPEO DE FASE I-II 2014-12-12 due-trials
Other 2013-001476-37 SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - not-yet-due
Other 2014-002632-14 A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART not-yet-due
Ongoing 2015-000203-89 Multi-centre, randomised, open label, phase IIb study to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and infant... not-yet-due